Ann Marie Rustia
Family · Baltimore, MDNPI 1992039622
Payments from drug & device makers
Across 285 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$862
- AbbVie$486
- Novo Nordisk$468
- GSK$444
- AstraZeneca$418
- Boehringer Ingelheim$374
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,40698%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 45 | $862 |
| AbbVie | 26 | $486 |
| Novo Nordisk | 34 | $468 |
| GSK | 22 | $444 |
| AstraZeneca | 19 | $418 |
| Boehringer Ingelheim | 20 | $374 |
| Bayer | 15 | $361 |
| Astellas Pharma US Inc | 14 | $351 |
| Amgen(2 entities) | 16 | $274 |
| Esperion Therapeutics, Inc. | 10 | $172 |
| Sanofi-aventis U.S. LLC | 7 | $150 |
| Pfizer | 8 | $137 |
| Dexcom, Inc. | 6 | $119 |
| Merck | 7 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $87 |
| Mylan Specialty L.p. | 3 | $84 |
| Novartis | 3 | $67 |
| Inspire Medical Systems, Inc. | 1 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $55 |
| Johnson & Johnson | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Corcept Therapeutics | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Exact Sciences | 1 | $27 |
| Nevro Corp. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Medtronic | 1 | $15 |
| Boston Scientific | 1 | $15 |
How this compares
$5,505 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 56 | $96,693 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $84,856 |
| OzempicSemaglutide | 37 | $71,306 |
| JardianceEmpagliflozin | 63 | $70,190 |
| EliquisApixaban | 44 | $48,641 |
| TrulicityDulaglutide | 17 | $44,457 |
| ProliaDenosumab | 22 | $38,055 |
| RybelsusSemaglutide | 15 | $29,586 |
| JanuviaSitagliptin Phosphate | 16 | $23,405 |
| XifaxanRifaximin | 13 | $22,812 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $10,474 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $5,465 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $5,090 |
| NexletolBempedoic Acid | 12 | $4,644 |
| Fenofibrate | 37 | $4,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $862 | $141,15073 claims |
| Novo NordiskOzempic, Rybelsus | $468 | $100,89352 claims |
| GSKTrelegy Ellipta | $444 | $84,85670 claims |
| Boehringer IngelheimJardiance | $374 | $70,19063 claims |
| PfizerEliquis | $137 | $48,64144 claims |
| AmgenProlia | $274 | $38,05522 claims |
| MerckJanuvia | $108 | $23,40516 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $87 | $22,81213 claims |
| Esperion Therapeutics, Inc.Nexletol | $172 | $4,64412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Baltimore
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Lisa ScottiBaltimore$35K
- Leah HartBaltimore$32K
- Jinae ArneklevBaltimore$24K
- Valerie OwenBaltimore$12K
- Eldho ChackoBaltimore$12K
- Melonie OwusuBaltimore$10K
- Amanda NevinBaltimore$9K
- Suryamol ChackoBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.